Literature DB >> 10945501

Down-regulation of TGF-beta1 production restores immunogenicity in prostate cancer cells.

E Matthews1, T Yang, L Janulis, S Goodwin, S D Kundu, W J Karpus, C Lee.   

Abstract

The objective of this study is to determine if a non-immunogenic Dunning's rat prostate cancer cell line, MATLyLu, can become immunogenic by reducing the endogenous production of TGF-beta1. An expression construct containing a DNA sequence in an antisense orientation to TGF-beta1 (TGF-beta1 antisense) was stably transfected into MATLyLu cells. Following transfection, cellular content of TGF-beta1 reduced from 70 to 10 pg per 2x10(4) cells and the rate of in vitro 3H-thymidine incorporation increased 3-5-fold. After subcutaneous injection of tumour cells into syngeneic male hosts (Copenhagen rats), the tumour incidence was 100% (15/15) for the wild type MATLyLu cells and cells transfected with the control construct, but only 43% (9/21, P< or =0.05) for cells transfected with TGF-beta1 antisense. However, when cells were injected into immunodeficient hosts (athymic nude rats), the incidence of tumour development was 100% (10/10) for both the wild type MATLyLu cells and cells transfected with the control construct and 90% (9/10) for cells transfected with TGF-beta1 antisense. These observations support the concept that MATLyLu cells are immunogenic, when the endogenous production of TGF-beta1 is down-regulated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10945501      PMCID: PMC2374659          DOI: 10.1054/bjoc.2000.1257

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  CD4+ suppressor cells inhibit the function of effector cells of experimental autoimmune encephalomyelitis through a mechanism involving transforming growth factor-beta.

Authors:  W J Karpus; R H Swanborg
Journal:  J Immunol       Date:  1991-02-15       Impact factor: 5.422

Review 2.  Regulation of immune responses by TGF-beta.

Authors:  J J Letterio; A B Roberts
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

Review 3.  TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity.

Authors:  E R Barrack
Journal:  Prostate       Date:  1997-04-01       Impact factor: 4.104

Review 4.  The molecular basis of allorecognition.

Authors:  L A Sherman; S Chattopadhyay
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

5.  Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential.

Authors:  D R Welch; A Fabra; M Nakajima
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

6.  Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro.

Authors:  M S Steiner; E R Barrack
Journal:  Mol Endocrinol       Date:  1992-01

7.  Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines.

Authors:  J Vieweg; F M Rosenthal; R Bannerji; W D Heston; W R Fair; B Gansbacher; E Gilboa
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

8.  Modulation of transforming growth factor beta 1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix.

Authors:  D M Morton; E R Barrack
Journal:  Cancer Res       Date:  1995-06-15       Impact factor: 12.701

9.  Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy.

Authors:  H Fakhrai; O Dorigo; D L Shawler; H Lin; D Mercola; K L Black; I Royston; R E Sobol
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

10.  Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane.

Authors:  E Y Yang; H L Moses
Journal:  J Cell Biol       Date:  1990-08       Impact factor: 10.539

View more
  6 in total

Review 1.  Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance.

Authors:  Shaun McKenzie; Natasha Kyprianou
Journal:  J Cell Biochem       Date:  2006-01-01       Impact factor: 4.429

Review 2.  Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.

Authors:  Yundong He; Weidong Xu; Yu-Tian Xiao; Haojie Huang; Di Gu; Shancheng Ren
Journal:  Signal Transduct Target Ther       Date:  2022-06-24

3.  PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.

Authors:  In-Young Jung; Simon F Lacey; Andrew J Rech; Megan M Davis; Carl H June; Joseph A Fraietta; Naomi B Haas; Vivek Narayan; Julie S Barber-Rotenberg; Wei-Ting Hwang; Priti Lal; Erica L Carpenter; Shannon L Maude; Gabriela Plesa; Neha Vapiwala; Anne Chew; Michael Moniak; Ronnie A Sebro; Michael D Farwell; Amy Marshall; Joan Gilmore; Lester Lledo; Karen Dengel; Sarah E Church; Tyler D Hether; Jun Xu; Mercy Gohil; Thomas H Buckingham; Stephanie S Yee; Vanessa E Gonzalez; Irina Kulikovskaya; Fang Chen; Lifeng Tian; Kyle Tien; Whitney Gladney; Christopher L Nobles; Hayley E Raymond; Elizabeth O Hexner; Donald L Siegel; Frederic D Bushman
Journal:  Nat Med       Date:  2022-03-21       Impact factor: 87.241

Review 4.  Mysteries of TGF-β Paradox in Benign and Malignant Cells.

Authors:  Qiang Zhang; Nengwang Yu; Chung Lee
Journal:  Front Oncol       Date:  2014-05-13       Impact factor: 6.244

5.  Effect of a Single Bout of Aerobic Exercise on Kynurenine Pathway Metabolites and Inflammatory Markers in Prostate Cancer Patients-A Pilot Randomized Controlled Trial.

Authors:  Alexander Schenk; Tobias Esser; André Knoop; Mario Thevis; Jan Herden; Axel Heidenreich; Wilhelm Bloch; Niklas Joisten; Philipp Zimmer
Journal:  Metabolites       Date:  2020-12-23

Review 6.  On-Target Anti-TGF-β Therapies Are Not Succeeding in Clinical Cancer Treatments: What Are Remaining Challenges?

Authors:  Adilson Fonseca Teixeira; Peter Ten Dijke; Hong-Jian Zhu
Journal:  Front Cell Dev Biol       Date:  2020-07-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.